[go: up one dir, main page]

MX2019002979A - Formulaciones de anticuerpos. - Google Patents

Formulaciones de anticuerpos.

Info

Publication number
MX2019002979A
MX2019002979A MX2019002979A MX2019002979A MX2019002979A MX 2019002979 A MX2019002979 A MX 2019002979A MX 2019002979 A MX2019002979 A MX 2019002979A MX 2019002979 A MX2019002979 A MX 2019002979A MX 2019002979 A MX2019002979 A MX 2019002979A
Authority
MX
Mexico
Prior art keywords
formulations
antibodies
antibody
methods
including pharmaceutical
Prior art date
Application number
MX2019002979A
Other languages
English (en)
Inventor
Deshmukh Ajay
Zeid Joumana
M Scherer Thomas
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2019002979A publication Critical patent/MX2019002979A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Se proporcionan formulaciones que comprenden un anticuerpo anti-IL-13, incluyendo formulaciones farmacéuticas y métodos de uso de dichas formulaciones.
MX2019002979A 2011-10-31 2014-04-24 Formulaciones de anticuerpos. MX2019002979A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161553916P 2011-10-31 2011-10-31

Publications (1)

Publication Number Publication Date
MX2019002979A true MX2019002979A (es) 2020-02-10

Family

ID=48192677

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014004992A MX363226B (es) 2011-10-31 2012-10-30 Formulaciones de anticuerpos.
MX2019002979A MX2019002979A (es) 2011-10-31 2014-04-24 Formulaciones de anticuerpos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014004992A MX363226B (es) 2011-10-31 2012-10-30 Formulaciones de anticuerpos.

Country Status (27)

Country Link
US (3) US10000562B2 (es)
EP (3) EP3091029B1 (es)
JP (4) JP6120452B2 (es)
KR (4) KR20140084078A (es)
CN (4) CN104039826A (es)
AR (2) AR088579A1 (es)
AU (3) AU2012332767C1 (es)
BR (1) BR112014008864B1 (es)
CA (2) CA3078979C (es)
DK (1) DK3091029T5 (es)
ES (1) ES2936387T3 (es)
FI (1) FI3091029T3 (es)
HK (1) HK1201857A1 (es)
HR (1) HRP20230153T1 (es)
HU (1) HUE061728T2 (es)
IL (2) IL232053B (es)
LT (1) LT3091029T (es)
MX (2) MX363226B (es)
MY (2) MY187874A (es)
PL (1) PL3091029T3 (es)
PT (1) PT3091029T (es)
RS (1) RS63948B1 (es)
RU (1) RU2665810C2 (es)
SG (1) SG11201401903PA (es)
SI (1) SI3091029T1 (es)
WO (1) WO2013066866A1 (es)
ZA (2) ZA201401779B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
CA3101119C (en) 2011-06-24 2023-07-04 Kci Licensing, Inc. Reduced-pressure dressings employing tissue-fixation elements
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
LT2771031T (lt) 2011-10-28 2018-08-27 Prothena Biosciences Limited Humanizuoti antikūnai, kurie atpažįsta alfa sinukleiną
HK1201857A1 (en) 2011-10-31 2015-09-11 F. Hoffmann-La Roche Ag Antibody formulations
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
UA115439C2 (uk) 2012-01-27 2017-11-10 Протена Біосаєнсиз Лімітед Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CN105722532A (zh) 2013-09-13 2016-06-29 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
BR112016004437A2 (pt) 2013-09-13 2017-10-17 Genentech Inc métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
JPWO2015079977A1 (ja) * 2013-11-26 2017-03-16 シャープ株式会社 抗体分離方法、抗体評価方法、医薬の評価方法、及び、抗体の２次元電気泳動用キット
WO2015155694A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
WO2021108427A1 (en) * 2019-11-26 2021-06-03 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
JP6798993B2 (ja) 2014-12-23 2020-12-09 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ボツリヌス毒素プレフィルド容器
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
US11077151B2 (en) * 2016-08-25 2021-08-03 California Institute Of Technology Ascaroside treatment of autoimmune and inflammatory diseases
JP6995844B2 (ja) * 2016-09-23 2022-02-04 ジェネンテック， インコーポレイテッド アトピー性皮膚炎を治療するためのｉｌ－１３アンタゴニストの使用
AU2018207367B2 (en) * 2017-01-11 2024-02-15 Celltrion Inc. Stable Liquid Formula
JP2019048091A (ja) * 2018-10-23 2019-03-28 ニプロ株式会社 デクスメデトミジン注射液を充填したプレフィルドシリンジ
AU2019333836B2 (en) * 2019-01-02 2023-11-09 Tosoh Corporation Light scattering detectors and methods for the same
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
CA3199246A1 (en) * 2020-10-22 2022-04-28 Allakos Inc. Anti-siglec-8 antibody formulations
TWI847170B (zh) 2021-07-16 2024-07-01 美商德米拉股份有限公司 用於治療異位性皮炎之il-13抗體
TWI859566B (zh) 2021-08-13 2024-10-21 美商德米拉股份有限公司 用於治療異位性皮膚炎之il-13抗體
WO2023044313A1 (en) 2021-09-15 2023-03-23 Dermira, Inc. Il-13 inhibitors for the treatment of prurigo nodularis
CN119630699A (zh) 2022-05-05 2025-03-14 德米拉公司 用于治疗特应性皮炎的il-13抗体
EP4540284A2 (en) 2022-06-17 2025-04-23 Apogee Therapeutics, Inc. Antibodies that bind interleukin 13 and methods of use
KR20250154502A (ko) 2023-03-08 2025-10-28 더미라, 인코포레이티드 아토피성 피부염의 치료를 위한 il-13 항체
WO2025076280A1 (en) 2023-10-05 2025-04-10 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders
WO2025128990A1 (en) 2023-12-14 2025-06-19 Dermira, Inc. Il-13 antibodies for the treatment of perennial allergic rhinitis
WO2025128984A1 (en) 2023-12-14 2025-06-19 Dermira, Inc. Il-13 antibodies for the treatment of chronic rhinosinusitis with nasal polyps
WO2025137523A2 (en) * 2023-12-20 2025-06-26 Apogee Therapeutics, Inc. Pharmaceutical formulations of antibodies that bind interleukin 13
TW202535935A (zh) * 2023-12-20 2025-09-16 美商艾普吉醫療股份有限公司 結合介白素13之抗體之醫藥組合物
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
WO2025155802A1 (en) * 2024-01-19 2025-07-24 Allakos Inc. Anti-siglec-6 antibody formulations
WO2025184453A1 (en) 2024-03-01 2025-09-04 Dermira, Inc. Il-13 antibodies for the treatment of post-inflammatory hyperpigmentation or hypopigmentation of skin

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
ES2151541T3 (es) 1992-12-02 2001-01-01 Alkermes Inc Microesferas que contienen hormona del crecimiento de liberacion prolongada.
BR9509201A (pt) 1994-09-09 1997-12-30 Takeda Chemical Industries Ltd Preparação de liberação sustemtada uso de um sal de metal polivalente insolúvel em água ou ligeiramente solúvel em água e processo para produzir uma preparação de liberação sustentada
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
EP0831787B1 (en) 1995-06-07 2001-08-22 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of human growth hormone
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2003512821A (ja) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド 外来性遺伝子の転写調節方法
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
JP4533626B2 (ja) * 2001-11-07 2010-09-01 サイトス バイオテクノロジー アーゲー アレルギー性好酸球性疾患を治療するための抗原アレイ
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
ES2304602T3 (es) * 2003-02-28 2008-10-16 Ares Trading S.A. Formulaciones liquidas de la proteina de union al factor de necrosis tumoral tbp-1.
DK1610820T4 (da) 2003-04-04 2013-11-04 Genentech Inc Høj-koncentration antistof- og proteinformuleringer
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
AR045614A1 (es) * 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
PL1711528T3 (pl) * 2003-12-23 2012-11-30 Genentech Inc Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2009510046A (ja) 2005-09-30 2009-03-12 メドイミューン・リミテッド インターロイキン−１３抗体組成物
MY144906A (en) * 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
WO2007076062A2 (en) * 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
TWI395754B (zh) * 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
CN101600457B (zh) * 2007-01-09 2014-01-08 惠氏公司 抗il-13抗体调配物和其用途
CA2676881C (en) * 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
PL2367542T3 (pl) * 2008-12-03 2014-05-30 Astellas Deutschland Gmbh Doustne formy dawkowania bendamustyny
CA2754528A1 (en) * 2009-03-06 2010-09-10 Genetech, Inc. Antibody formulation
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
KR102218495B1 (ko) * 2010-03-22 2021-02-19 제넨테크, 인크. 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
JP2013525484A (ja) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
JP6024025B2 (ja) 2011-05-02 2016-11-09 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 少容量投与用のアロタイプ選択抗体の限外濾過濃縮
HK1201857A1 (en) * 2011-10-31 2015-09-11 F. Hoffmann-La Roche Ag Antibody formulations

Also Published As

Publication number Publication date
AR124140A2 (es) 2023-02-15
RU2014116070A (ru) 2015-12-10
KR20140084078A (ko) 2014-07-04
EP2773662A1 (en) 2014-09-10
KR20190077127A (ko) 2019-07-02
EP4218937A3 (en) 2023-10-25
MY197851A (en) 2023-07-20
LT3091029T (lt) 2023-02-27
IL232053A0 (en) 2014-05-28
JP2016193922A (ja) 2016-11-17
US20190002552A1 (en) 2019-01-03
FI3091029T3 (fi) 2023-03-20
MX363226B (es) 2019-03-15
US20210155684A1 (en) 2021-05-27
SG11201401903PA (en) 2014-05-29
ZA201401779B (en) 2019-07-31
RU2665810C2 (ru) 2018-09-04
BR112014008864A2 (pt) 2018-08-07
CA3078979A1 (en) 2013-05-10
ES2936387T3 (es) 2023-03-16
JP6921148B2 (ja) 2021-08-18
AU2018232943A1 (en) 2018-10-11
HK1201857A1 (en) 2015-09-11
PL3091029T3 (pl) 2023-04-11
CN108704132A (zh) 2018-10-26
KR101994809B1 (ko) 2019-07-01
BR112014008864B1 (pt) 2021-11-09
WO2013066866A1 (en) 2013-05-10
MX2014004992A (es) 2014-08-27
EP3091029A1 (en) 2016-11-09
AU2012332767C1 (en) 2017-02-02
DK3091029T5 (da) 2024-10-14
EP4218937A2 (en) 2023-08-02
IL232053B (en) 2020-08-31
JP2019203002A (ja) 2019-11-28
AR088579A1 (es) 2014-06-18
AU2012332767A1 (en) 2014-04-10
HUE061728T2 (hu) 2023-08-28
CN109078182B (zh) 2022-08-12
CA2849210A1 (en) 2013-05-10
EP3091029B1 (en) 2022-12-28
CN109078182A (zh) 2018-12-25
KR20170096212A (ko) 2017-08-23
US20140348855A1 (en) 2014-11-27
AU2018232943B2 (en) 2020-07-23
HRP20230153T1 (hr) 2023-03-31
JP2014532664A (ja) 2014-12-08
MY187874A (en) 2021-10-26
PT3091029T (pt) 2023-02-03
CN104039826A (zh) 2014-09-10
US10947307B2 (en) 2021-03-16
JP6120452B2 (ja) 2017-04-26
JP2018048166A (ja) 2018-03-29
CA3078979C (en) 2022-10-11
KR20200065104A (ko) 2020-06-08
SI3091029T1 (sl) 2023-03-31
US10000562B2 (en) 2018-06-19
ZA201901490B (en) 2021-06-30
IL276234A (en) 2020-09-30
KR102259829B1 (ko) 2021-06-03
CN116077644A (zh) 2023-05-09
NZ622654A (en) 2017-01-27
CA2849210C (en) 2020-07-14
RS63948B1 (sr) 2023-02-28
AU2016210757A1 (en) 2016-08-25
AU2012332767B2 (en) 2016-05-12
DK3091029T3 (da) 2023-01-30
JP6272950B2 (ja) 2018-01-31
IL276234B (en) 2022-04-01
US12492247B2 (en) 2025-12-09
EP2773662A4 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
MX2019002979A (es) Formulaciones de anticuerpos.
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
CR20160141A (es) Formulaciones de anticuerpos anti-pdl1
CO6721041A2 (es) Anticuerpo anti-pcsk9 y métodos de uso
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
CL2015000582A1 (es) Anticuerpos anti-mcam y métodos asociados de uso
EA201790664A1 (ru) Антитела против мезотелина и иммуноконъюгаты
PE20150646A1 (es) Metodos de tratamiento de una tauopatia
MX380520B (es) Anticuerpos receptores de antitransferina y métodos de uso.
CO6771458A2 (es) Conjugados de anticuerpo-fármaco
BR112015007120A2 (pt) anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
AR090923A1 (es) Anticuerpos anti-il-23
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
ECSP13012440A (es) Anticuerpos anti-fap y métodos de uso
MX375020B (es) Anticuerpos anti-alfa-sinucleina y métodos de uso.
AR088920A1 (es) Purificacion de anticuerpos anti-c-met
CR20110544A (es) Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7
MY170720A (en) Antibody formulations
CL2014001640A1 (es) Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
ECSP13012536A (es) Composiciones de anticuerpo y métodos de uso